http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Article/list/43981 Written by Physicians, For Physicians Ophthalmology Times is an award-winning physician-driven publication that disseminates news and information of a clinical, socio-economic, and political nature in a timely and accurate manner for members of the ophthalmic community. 2009-11-21T07:26:09Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/FDA-approves-Sirions-NDA-for-ganciclovir-015-for-h/ArticleStandard/Article/detail/631228?contextCategoryId=43981&ref=25 The FDA has approved a new drug application (NDA) for ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) as a treatment for acute herpetic keratitis (dendritic ulcers), the company announced. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631228null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/World-Sight-Day-set-for-Oct-8/ArticleStandard/Article/detail/631236?contextCategoryId=43981&ref=25 Three hundred events in more than 50 countries will mark this year's World Sight Day, Oct. 8. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631236null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Presbia-unveils-implantable-micro-lens/ArticleStandard/Article/detail/631234?contextCategoryId=43981&ref=25 Presbia Coöperatief U.A. of Amsterdam unveiled an implantable micro-lens treatment (Flexivue System) for presbyopia at the European Society of Cataract and Refractive Surgeons annual meeting. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631234null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/AMD-Alliance-International-organizes-video-contest/ArticleStandard/Article/detail/631188?contextCategoryId=43981&ref=25 AMD Alliance International is hosting a video contest to raise awareness for age-related macular degeneration (AMD). Individuals are invited to create and submit videos of no longer than 3 minutes that will communicate in the most creative and visually interesting ways the impact of AMD. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/402009/631188null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Allergan-Pieris-AG-agreement-targets-anticalin-for/ArticleStandard/Article/detail/626937?contextCategoryId=43981&ref=25 Pieris AG announced that it has entered into a collaboration agreement with Allergan Inc. that will combine Pieris' proprietary anticalin technology with Allergan's drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626937null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Ganciclovir-ophthalmic-gel-015-approved-by-FDA-for/ArticleStandard/Article/detail/626936?contextCategoryId=43981&ref=25 Sirion Therapeutics Inc. announced the FDA approval of its new drug application for ganciclovir ophthalmic gel 0.15% (Zirgan) as a treatment for acute herpetic keratitis. The FDA granted orphan drug designation to the gel for this indication in April 2007. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626936null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/FDA-approves-bepotastine-drops-for-ocular-itching/ArticleStandard/Article/detail/626550?contextCategoryId=43981&ref=25 The FDA has approved bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626550null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Surgeon-outlines-technique-intraoperative-fi/ArticleStandard/Article/detail/626886?contextCategoryId=43981&ref=25 Surgeons should not use home-made solutions or riboflavin in their corneal cross-linking technique, as it leads to unreliable results, said Paolo Vinciguerra, MD. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626886null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Biomechanics-of-the-crossed-link-cornea-expl/ArticleStandard/Article/detail/626885?contextCategoryId=43981&ref=25 The next steps in the evolution of corneal cross linking (CXL) therapy must seek to improve the penetration of riboflavin to the deepest corneal layers, said Jesper Hjortdal, MD, PhD. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626885null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Two-new-imaging-device-models-are-available/ArticleStandard/Article/detail/626557?contextCategoryId=43981&ref=25 Heidelberg Engineering has two new models in its family of multimodality ophthalmic imaging devices (Spectralis). 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626557null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Femtosecond-laser-receives-clearance-for-capsuloto/ArticleStandard/Article/detail/626558?contextCategoryId=43981&ref=25 LenSx Lasers Inc. announced that the FDA has granted 510(k) clearance for its femtosecond laser used for anterior capsulotomy during cataract surgery. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626558null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ISTA-reports-preliminary-results-for-investigation/ArticleStandard/Article/detail/626562?contextCategoryId=43981&ref=25 ISTA Pharmaceuticals has announced preliminary results from two recently completed studies of its investigational eye drop, prednisolone acetate 1.0% and tobramycin 0.3% (T-Pred). 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626562null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Results-of-cross-linking-for-corneal-melting/ArticleStandard/Article/detail/626884?contextCategoryId=43981&ref=25 Corneal cross-linking (CXL) can help treat corneal melting, said Theo Seiler, MD, PhD. 2009-09-16T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626884null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-A-review-of-the-role-and-efficacy-of-anti-VE/ArticleStandard/Article/detail/626532?contextCategoryId=43981&ref=25 A review of the role and efficacy of anti-VEGF therapy in macular disease 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626532null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Combined-cataract-and-vitreoretinal-surgery/ArticleStandard/Article/detail/626533?contextCategoryId=43981&ref=25 Combined pars plana vitrectomy and cataract surgery is a safe and effective procedure that allows the surgeon to avoid performing a second operation, but adequate treatment is recommended to all patients over 60 years. 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626533null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Cataract-surgery-in-patients-with-pre-existi/ArticleStandard/Article/detail/626534?contextCategoryId=43981&ref=25 Ophthalmologists should not dismiss cataract surgery for patients with pre-existing age-related macular degeneration out of hand because they are afraid of the risks. 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626534null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/FDA-resumes-review-of-toric-implantable-contact-le/ArticleStandard/Article/detail/627817?contextCategoryId=43981&ref=25 The FDA will resume scientific review of the STAAR Surgical Co. premarket approval (PMA) application for its toric implantable contact lens ([TICL]; Visian Toric Implantable Collamer Lens) for patients with myopia and astigmatism after removing the "integrity hold" restrictions it put in place in 2007, according to the company. 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627817null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Super-vision-Myth-and-reality/ArticleStandard/Article/detail/626531?contextCategoryId=43981&ref=25 Ophthalmic technology has advanced phenomenally over the past 30 years and ophthalmology is now working towards super vision, but researchers and innovators need to take the time to reflect on the impact of technological change. 2009-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626531null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Corneal-stromal-effects-and-profiles-with-de/ArticleStandard/Article/detail/626112?contextCategoryId=43981&ref=25 Femtosecond laser ablation of the deep corneal stroma is a viable alternative to microkeratome donor preparation for DSAEK and DALK. 2009-09-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626112null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-New-insights-into-ectopia-lentis/ArticleStandard/Article/detail/626113?contextCategoryId=43981&ref=25 Systemic associations are common in cases of ectopia lentis and it may have general health implications. 2009-09-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626113null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Project-Gullstrand-Ocular-biometry-and-stray/ArticleStandard/Article/detail/626118?contextCategoryId=43981&ref=25 Soft contact lenses can induce greater straylight issues in long-term users but those effects appear to be improved by LASEK surgery. 2009-09-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626118null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Anterior-chamber-lenses-in-the-management-of/ArticleStandard/Article/detail/626114?contextCategoryId=43981&ref=25 Ophthalmology needs a large-scale, probably multicentre prospective trial to fully understand and codify the management of subluxated lenses. 2009-09-14T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626114null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-PRK-and-LASEK-in-children/ArticleStandard/Article/detail/626075?contextCategoryId=43981&ref=25 It is important for surgeons to put the IOL in the bag in children's eyes and to do this securely, surgeons must perform anterior and posterior rhexis. 2009-09-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626075null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Confocal-microscopy-as-an-evaluation-tool-of/ArticleStandard/Article/detail/626073?contextCategoryId=43981&ref=25 Confocal microscopy as an evaluation tool of wound healing in corneal surgery 2009-09-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626073null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-IOLs-anatomical-prerequisites-for-accommodat/ArticleStandard/Article/detail/626074?contextCategoryId=43981&ref=25 Ophthalmologists must improve IOL sizing, its position on the optical axis and IOL centration and tilt if they want to achieve accommodation. 2009-09-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626074null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ESCRS-Anterior-and-posterior-capsulorhexis-in-chil/ArticleStandard/Article/detail/626079?contextCategoryId=43981&ref=25 Refractive surgery in children should be limited to those who have no alternative. 2009-09-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/626079null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/DSEK-shown-to-be-safe-effective-therapy-according-/ArticleStandard/Article/detail/624925?contextCategoryId=43981&ref=25 Descemet's stripping endothelial Keratoplasty (DSEK) was shown to be a safe and effective treatment for corneal endothelial diseases, according to a 2009 review by the cornea panel of the American Academy of Ophthalmology's (AAO) Ophthalmic Technology Assessment Committee, led by W. Barry Lee, MD. 2009-09-08T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372009/624925null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Hoya-Surgical-Optics-introduces-preloaded-IOL-inje/ArticleStandard/Article/detail/623227?contextCategoryId=43981&ref=25 Hoya Surgical Optics has introduced a preloaded IOL injection system (iSert) in the United States. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623227null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ISTA-to-seek-bromfenac-label-change/ArticleStandard/Article/detail/623208?contextCategoryId=43981&ref=25 ISTA Pharmaceuticals plans to ask the FDA to approve a change to the label of its bromfenac 0.09% ophthalmic solution after obtaining positive preliminary phase III results in a confirmatory clinical study of once-daily bromfenac (Xibrom QD) for the treatment of inflammation and pain after cataract surgery. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623208null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Aton-expands-programs-for-preservative-free-timolo/ArticleStandard/Article/detail/623228?contextCategoryId=43981&ref=25 Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States. 2009-09-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/362009/623228null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Anti-inflammatory-for-cataract-surgery-reaches-pha/ArticleStandard/Article/detail/621767?contextCategoryId=43981&ref=25 Preliminary phase III results were released for bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals), meant to treat the inflammation and pain following cataract surgery. 2009-08-26T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/352009/621767null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Lowering-levels-of-arginase-may-halt-progression-o/ArticleStandard/Article/detail/621078?contextCategoryId=43981&ref=25 High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy, according to researchers at the Medical College of Georgia (MCG) School of Medicine. 2009-08-24T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/352009/621078null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Rapid-pink-eye-tests-are-now-available-in-one-stat/ArticleStandard/Article/detail/619820?contextCategoryId=43981&ref=25 MinuteClinic now offers a rapid conjunctivitis test at its 23 locations inside select pharmacy stores in the Atlanta area, according to a prepared statement. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619820null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Survey-shows-cataract-surgery-times-can-be-decreas/ArticleStandard/Article/detail/619783?contextCategoryId=43981&ref=25 Ambulatory centers performing cataract extraction with lens insertion can reduce their procedure times and improve efficiencies, safety, and patient satisfaction, according to a survey conducted by the Accreditation Association for Ambulatory Health Care Institute for Quality Improvement. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619783null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Botulinum-toxin-products-display-warnings-receive-/ArticleStandard/Article/detail/619785?contextCategoryId=43981&ref=25 The FDA announced that four botulinum toxin drug products now have boxed warnings on their labels and include medication guides that explain the risk of adverse events to patients, as directed by the agency in April. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619785null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/New-antihistamine-eye-drop-controls-itchy-eyes/ArticleStandard/Article/detail/619818?contextCategoryId=43981&ref=25 Schering-Plough Corp. has launched an antihistamine eye drop (Claritin Eye) designed to control the itch of allergy eyes for up to 12 hours. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619818null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Alcons-toric-lens-is-designated-as-NTIOL/ArticleStandard/Article/detail/619984?contextCategoryId=43981&ref=25 Alcon Inc. has announced that the Centers for Medicare and Medicaid Services (CMS) have approved the inclusion of its latest toric IOL (AcrySof IQ) in the reduced spherical aberration class of New Technology Intraocular Lenses (NTIOL). 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619984null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Research-shows-children-would-benefit-from-compreh/ArticleStandard/Article/detail/619789?contextCategoryId=43981&ref=25 A new report from the National Commission on Vision and Health concludes that even though universal comprehensive eye exams for children conducted prior to starting school would result in more vision problems and eye diseases being diagnosed and treated successfully in children, requirements vary widely from state to state, and only three states require eye examinations for school-aged children. 2009-08-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342009/619789null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Anti-VEGF-found-to-improve-vision-when-used-for-pa/ArticleStandard/Article/detail/617166?contextCategoryId=43981&ref=25 In a study conducted by the Pan-American Collaborative Retina Study Group, treatment of diffuse diabetic macular edema with bevacizumab (Avastin, Genentech) was shown to improve vision. 2009-08-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/322009/617166null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cataract/Ketolorac-tromethamine-should-be-available-in-Sept/ArticleStandard/Article/detail/615682?contextCategoryId=43981&ref=25 Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615682null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/SOLX-receives-clearance-for-glaucoma-implant-use-i/ArticleStandard/Article/detail/615732?contextCategoryId=43981&ref=25 SOLX has received clearance from Health Canada for the use of its 24-karat gold implant (SOLX Gold Shunt) during glaucoma surgery. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615732null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/FDA-to-resume-review-of-STAARs-implantable-contact/ArticleStandard/Article/detail/615731?contextCategoryId=43981&ref=25 The FDA will resume scientific review of the STAAR Surgical Co. premarket approval (PMA) application for its toric implantable contact lens ([TICL]; Visian Toric Implantable Collamer Lens) for patients with myopia and astigmatism after removing the "integrity hold" restrictions it put in place in 2007, according to the company. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615731null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Bausch-amp-Lomb-lens-designed-for-implantation-thr/ArticleStandard/Article/detail/616504?contextCategoryId=43981&ref=25 The spherical aberration-free lens has been developed specifically for 1.8-mm microincision cataract surgery (MICS), and the company said it will refer to the lens within the United States as the Akreos MICS. Its award-winning design and glistening-free material allow implantation through a 1.8-mm incision, while maintaining the optical quality and stability established with the parent lens design (Akreos AO). 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/322009/616504null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ANV-therapy-system-receives-CE-mark-approval/ArticleStandard/Article/detail/616506?contextCategoryId=43981&ref=25 NeoVista Inc. received approval from BSI Product Services to apply the CE mark to its anti-neovascular (ANV) therapy system (Vidion) to treat wet age-related macular degeneration (AMD), the company announced. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/322009/616506null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/WaveLight-AG-announces-news-of-excimer-femtosecond/ArticleStandard/Article/detail/615735?contextCategoryId=43981&ref=25 Japanese authorities have granted WaveLight AG regulatory approval to market its 200-Hz excimer laser system (Allegretto Wave) for use in wavefront-optimized LASIK treatments of myopia and myopic astigmatism there, according to the company. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615735null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Researchers-uncover-genetic-link-to-age-related-ca/ArticleStandard/Article/detail/615695?contextCategoryId=43981&ref=25 Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. 2009-08-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/615695null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Tamsulosin-intraoperative-floppy-iris-syndrome-lin/ArticleStandard/Article/detail/617060?contextCategoryId=43981&ref=25 A recent article in the Journal of the American Medical Association, an editorial in American Family Physician, articles in the general media outlets, and an updated patient advisory statement from the American Society of Cataract and Refractive Surgery and the American Academy of Ophthalmology aim to further education primary care physicians and patients about the association between a patient's use of tamsulosin and complications or difficulty during cataract surgery. 2009-08-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/322009/617060null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Contact-lenses-effective-for-medication-delivery-a/ArticleStandard/Article/detail/614393?contextCategoryId=43981&ref=25 Drug-releasing contact lenses may provide correct and consistent dosages of medication for patients, according to findings published in Investigative Ophthalmology & Visual Science. 2009-07-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/614393null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Learning-disabilities-not-caused-by-vision-problem/ArticleStandard/Article/detail/614389?contextCategoryId=43981&ref=25 No scientific evidence supports the view that subtle eye or visual problems cause learning disabilities, according to a revised policy statement on learning disabilities, dyslexia, and vision issued by the American Academy of Ophthalmology. 2009-07-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/312009/614389null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Genentech-reports-positive-results-in-phase-III-st/ArticleStandard/Article/detail/610825?contextCategoryId=43981&ref=25 Ranibizumab (Lucentis, Genentech) improved vision in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) when compared with sham injections, according to results of a phase III study announced by Genentech. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610825null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Accommodating-IOL-in-quarter-diopter-steps-receive/ArticleStandard/Article/detail/610817?contextCategoryId=43981&ref=25 Bausch & Lomb announced that it has received approval from the FDA to market its proprietary fourth-generation accommodating IOL (Crystalens HD) in quarter-diopter steps in the United States. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610817null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Alcon-NovaBay-begin-phase-II-trial-of-NVC-422/ArticleStandard/Article/detail/610824?contextCategoryId=43981&ref=25 Alcon Inc. and NovaBay Pharmaceuticals have announced that Alcon has begun treating patients in a phase II clinical trial of NovaBay's lead proprietary compound (Aganocide), NVC-422, for viral conjunctivitis. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610824null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Besifloxacin-approved/ArticleStandard/Article/detail/618581?contextCategoryId=43981&ref=25 Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) is a new topical ophthalmic antibacterial indicated for the treatment of bacterial conjunctivitis and administered via sterile ophthalmic drops. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/332009/618581null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Ophthalmology/IOL-injector-system-given-510k-clearance/ArticleStandard/Article/detail/606849?contextCategoryId=43981&ref=25 The FDA has granted 510(k) clearance for an injector system (Epiphany, STAAR Surgical Co.) designed for use with a three-piece new-technology IOL ([NTIOL]; Affinity Collamer, STAAR Surgical) and a silicone NTIOL (Elastimide, STAAR Surgical), according to the devices' manufacturer. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606849null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Committee-recommends-approval-of-bepotastine-for-o/ArticleStandard/Article/detail/606848?contextCategoryId=43981&ref=25 The Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the FDA has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals Inc.) as an eye-drop treatment for ocular itching associated with allergic conjunctivitis, according to the company. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606848null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Glaucoma/Glaucoma-progression-software-receives-clearance-f/ArticleStandard/Article/detail/606851?contextCategoryId=43981&ref=25 Software (MatchedFlicker, EyeIC) that monitors the advent and progression of glaucoma through retinal photography has received FDA 510(k) clearance. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606851null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Besifloxacin-approved-for-use-against-ocular-infec/ArticleStandard/Article/detail/606445?contextCategoryId=43981&ref=25 Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) is a new topical ophthalmic antibacterial indicated for the treatment of bacterial conjunctivitis and administered via sterile ophthalmic drops. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606445null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Dry-eye-diagnosis-could-be-aided-by-tear-osmolarit/ArticleStandard/Article/detail/606431?contextCategoryId=43981&ref=25 The FDA has given 501(k) clearance to the TearLab Osmolarity System, a new device that measures the osmolarity of tears to aid in the diagnosis of dry eye disease. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606431null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Retina/FDA-approves-implant-for-macular-edema-associated-/ArticleStandard/Article/detail/606846?contextCategoryId=43981&ref=25 The FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion. 2009-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/606846null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Omega-3-fatty-acids-may-prevent-progression-of-AMD/ArticleStandard/Article/detail/605748?contextCategoryId=43981&ref=25 Omega-3 fatty acids found in fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD). 2009-06-22T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/262009/605748null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Dexamethasone-receives-FDA-approval-for-the-treatm/ArticleStandard/Article/detail/604831?contextCategoryId=43981&ref=25 Dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan), indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), has been approved by the FDA. Retinal vein occlusion including BRVO and CRVO is the second most common retinal vascular disease after diabetic retinopathy. 2009-06-18T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252009/604831null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/CCR3-linked-to-neovascular-AMD-according-to-resear/ArticleStandard/Article/detail/604488?contextCategoryId=43981&ref=25 Researchers identified a biological marker, CCR3, which is linked to the development and progression of neovascular age-related macular degeneration (AMD). 2009-06-17T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252009/604488null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/NT-501-demonstrates-strong-biologic-effect-on-phot/ArticleStandard/Article/detail/603397?contextCategoryId=43981&ref=25 An intraocular implant, NT-501, has demonstrated a strong biologic effect in two phase II clinical trials for retinitis pigmentosa (RP), according to a release issued by Neurotech Pharmaceuticals. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603397null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/RADICAL-study-shows-positive-12-month-results/ArticleStandard/Article/detail/603396?contextCategoryId=43981&ref=25 QLT Inc. has announced positive 12-month primary analysis results from a phase II study in patients with wet age-related macular degeneration (AMD), known as RADICAL (or Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions). 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603396null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Bromfenac-shows-positive-results-for-dry-eye-disea/ArticleStandard/Article/detail/603371?contextCategoryId=43981&ref=25 Results are positive from a proof-of-concept phase II clinical study in patients with dry eye disease using a proprietary, low-dose formulation of bromfenac, the active ingredient in bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals), the company announced. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603371null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/OCT-software-receives-FDA-clearance/ArticleStandard/Article/detail/603380?contextCategoryId=43981&ref=25 Carl Zeiss Meditec has announced that a new suite of optical coherence tomography (OCT) software applications for its proprietary high-definition OCT device (Cirrus) has received FDA clearance for commercial distribution. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603380null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Dry-eye-disease-more-common-in-American-men-as-the/ArticleStandard/Article/detail/603401?contextCategoryId=43981&ref=25 A study conducted at Brigham and Women's Hospital has found that dry eye disease is common among American men aged more than 50 years, and it increases with age, high blood pressure, occurrence of benign prostate disease, and the use of antidepressants, according to a prepared statement issued by the hospital, as researchers reported in a June issue of Archives of Ophthalmology. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603401null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/EGP-437-improves-dry-eye-signs-symptoms-in-phase-I/ArticleStandard/Article/detail/603390?contextCategoryId=43981&ref=25 A corticosteroid solution, EGP-437, administered by a proprietary noninvasive ocular drug delivery system showed improvement in signs and symptoms in patients with dry eye syndrome (DES) during a phase II study, according to a statement issued by EyeGate Pharma. 2009-06-12T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/603390null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cataract/AAO-ASCRS-issue-advisory-to-cataract-patients-taki/ArticleStandard/Article/detail/602877?contextCategoryId=43981&ref=25 The American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS) have issued a joint statement regarding results of a new study. The new research reinforces an advisory issued in 2006 that cautioned patients taking tamsulosin (Flomax, Boehringer Ingelheim Pharmaceuticals Inc.) to treat prostate enlargement and urinary problems should inform their ophthalmologist about use of this alpha-blocker before undergoing eye surgery. 2009-06-10T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602877null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Four-percent-of-older-US-men-have-dry-eye-disease/ArticleStandard/Article/detail/602488?contextCategoryId=43981&ref=25 Dry eye disease is common among American men aged more than 50 years and its prevalence increases with age, high blood pressure, benign prostrate disease, and the use of antidepressants, according to a report in the June issue of Archives of Ophthalmology. 2009-06-09T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602488null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Boys-with-intermittent-exotropia-more-likely-to-de/ArticleStandard/Article/detail/602491?contextCategoryId=43981&ref=25 Children with intermittent exotropia, especially boys, appear more likely to develop mental illness by young adulthood than children without strabismus, according to a report in the June issue of Archives of Ophthalmology 2009-06-09T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242009/602491null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Glaucoma-medication-adherence-linked-to-age-and-et/ArticleStandard/Article/detail/601974?contextCategoryId=43981&ref=25 Studies covering a range of chronic disease consistently show that only about 70% of prescribed medications are taken. Patients with glaucoma may not take their eye drops because they often have no pain, few symptoms, and treatment benefits are apparent over years rather than immediately. 2009-06-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601974null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Corneal-edema-patients-at-higher-risk-for-transpla/ArticleStandard/Article/detail/601688?contextCategoryId=43981&ref=25 The corneal transplant failure rate was four times higher in patients diagnosed with corneal edema associated with either IOL implants or no natural lens following cataract removal, than in patients diagnosed with Fuchs' dystrophy, according to a study. 2009-06-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601688null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Ocular-disorders-seen-with-use-of-cancer-drug-erlo/ArticleStandard/Article/detail/600379?contextCategoryId=43981&ref=25 New safety information has been added to the warnings and precautions sections of the prescribing information for the cancer drug erlotinib (Tarceva, Genentech and OSI), according to a letter sent to health-care professionals by the two companies and the FDA. 2009-06-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600379null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Newer-fluoroquinolones-effective-in-reducing-CNS-p/ArticleStandard/Article/detail/601241?contextCategoryId=43981&ref=25 A study was conducted at Yonsei University College of Medicine, South Korea, to evaluate the risk of infection in 105 patients. Conjunctiva swabs were taken immediately before LASIK, or similar refractive surgery, to measure pre-existing bacteria. 2009-06-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601241null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Pediatric-testing-system-assists-in-early-detectio/ArticleStandard/Article/detail/600347?contextCategoryId=43981&ref=25 Vision problems in children are not always easy to detect, according to Barry Goldman, MD, pediatrician, Children's Health Center in Gurnee, IL. 2009-05-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/600347null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Stem-cells-may-help-heal-damaged-retinal-tissue-ac/ArticleStandard/Article/detail/599871?contextCategoryId=43981&ref=25 Stem cells taken from bone marrow show promise in healing damaged retinal tissue, according to researchers at the University of Louisville. 2009-05-26T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222009/599871null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/AMD-and-reduced-cognitive-function-linked-accordin/ArticleStandard/Article/detail/598749?contextCategoryId=43981&ref=25 Dementia and age-related macular degeneration (AMD) could have a similar pathogenesis because of an association between AMD and reduced cognitive function in older people, according to a study. 2009-05-19T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/212009/598749null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/LASIK-research-continues-in-NEINIH-grant-by-Kansas/ArticleStandard/Article/detail/597967?contextCategoryId=43981&ref=25 Gary Conrad, PhD, has received a 4-year grant renewal of $1.48 million from the National Eye Institute for the National Institutes of Health (NEI/NIH) to study the cornea. Dr. Conrad is a university distinguished professor at Kansas State University's Division of Biology. 2009-05-13T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202009/597967null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Synaptic-organization-of-vertebrate-retina-ma/ArticleStandard/Article/detail/596804?contextCategoryId=43981&ref=25 Samuel M. Wu, PhD, has spent much of his career at the Cullen Eye Institute, Baylor College of Medicine, Houston, investigating the molecular, cellular, and synaptic mechanisms underlying signal processing systems in the retina as well as the synaptic mechanisms underlying eye diseases. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596804null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Mouse-model-examines-age-related-susceptibili/ArticleStandard/Article/detail/596789?contextCategoryId=43981&ref=25 Data from a mouse model suggest that aging increases retina and optic nerve vulnerability to IOP evaluation and associated oxidative stress. These experiments suggest a possible mechanism through which aging predisposes the eye to glaucoma, said Yu Xiang Kong, PhD, of the glaucoma research unit, Centre for Eye Research Australia, University of Melbourne. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596789null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Combined-index-of-optic-nerve-structure-funct/ArticleStandard/Article/detail/596799?contextCategoryId=43981&ref=25 Researchers at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, have developed a combined index of optic nerve structure, function, and anatomy to improve the detection of glaucoma. The structure function index (SFI) might perform better than either structure or function alone, said Michael V. Boland, MD, PhD, assistant professor of ophthalmology at the institute. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596799null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Ophthalmic+News/ARVO-Second-Sight-doubles-patient-enrollment-for-r/ArticleStandard/Article/detail/596778?contextCategoryId=43981&ref=25 Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596778null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Marie-Burns-PhD-receives-Cogan-Award-for-unra/ArticleStandard/Article/detail/596805?contextCategoryId=43981&ref=25 Marie Burns, PhD, received the Cogan Award for her work in retinal phototransduction. The award recognizes a young researcher who has made substantial contributions to work in ophthalmology or visual science directly related to ocular disorders and who also exhibits significant promise for future research. She is associate professor, Department of Ophthalmology and Visual Science, University of California-Davis. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596805null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Inspire-initiates-phase-II-trials-with-azithr/ArticleStandard/Article/detail/596780?contextCategoryId=43981&ref=25 Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596780null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Intravitreal-siRNA-PF-04523655-stabilized-vis/ArticleStandard/Article/detail/596802?contextCategoryId=43981&ref=25 Intravitreal small-interfering RNA (siRNA) PF-04523655 (Quark; licensed to Pfizer) used to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) seems to be safe and well tolerated in an interim phase I analysis. No adverse events were observed up to the 3,000-µg dose, said Quan Dong Nguyen, MD, MSc, assistant professor of ophthalmology, retina division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore. He reported the results for the siRNA PF-04523655 AMD Investigation. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596802null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Ranibizumab-safe-effective-over-long-term-in-/ArticleStandard/Article/detail/596803?contextCategoryId=43981&ref=25 Multiple intravitreal ranibizumab (Lucentis, Genentech) was safe and effective over the long term for treating subfoveal choroidal neovascularization (CNV) in age-related degeneration (AMD) in the 2-year open-label, multicenter HORIZON extension study, said Michael Singer, MD, Medical Center Ophthalmology Associates, San Antonio, TX. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596803null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Novagali-Pharma-IND-cleared-for-phase-III-stu/ArticleStandard/Article/detail/596779?contextCategoryId=43981&ref=25 Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596779null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Targeted-PDT-more-effective-in-stopping-leaka/ArticleStandard/Article/detail/596801?contextCategoryId=43981&ref=25 Factor VII (fVII)-verteporfin (Visudyne, Novartis) for targeted photodynamic therapy (PDT) significantly reduced leakage compared with non-targeted PDT in a rat model of choroidal neovascularization. The dose that was efficacious was about 1/10 that of the standard dose of PDT, said Ron Adelman, MD, MPH, Department of Ophthalmology, Yale University Eye Center, New Haven, CT. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596801null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Analysis-weighs-benefits-of-anti-VEGF-therapy/ArticleStandard/Article/detail/596777?contextCategoryId=43981&ref=25 Off-label treatment with intravitreal bevacizumab (Avastin, Genentech) resulted in regression of retinal neovascularization in patients with proliferative diabetic retinopathy (PDR) in a retrospective analysis performed by the Pan-American Collaborative Retina Study Group (PACORES). The benefits of bevacizumab therapy, however, decreased from the 6-month follow-up to 24 months, a development being studied further, said J. Fernando Arevalo, MD, FACS, director of ophthalmology at the Clinica Oftalmologica Centro Caracas in Caracas, Venezuela. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596777null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Cognitive-function-depression-may-be-risk-fac/ArticleStandard/Article/detail/596562?contextCategoryId=43981&ref=25 Data from a substudy within the Age-Related Eye Disease Study 2 (AREDS2) suggest that cognitive function and depression may be risk factors for progression to advanced age-related macular degeneration (AMD). The association only was found for general measures of cognitive function, however, said Traci E. Clemons, PhD, EMMES Corp., Rockville, MD. She also cautioned that it would be premature to place too much emphasis on the data, which were designed for hypothesis generation rather than testing. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596562null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Unique-fusion-protein-yields-stable-improveme/ArticleStandard/Article/detail/596559?contextCategoryId=43981&ref=25 A phase II update study highlighted factors predictive of visual acuity (VA) outcomes in patients with neovascular age-related macular degeneration (AMD) who were treated with repeated intravitreal injections of a unique fusion protein (VEGF Trap-Eye, Regeneron and Bayer HealthCare). Jeffrey S. Heier, MD, a vitreoretinal specialist affiliated with Ophthalmic Consultants of Boston, reported these results on behalf of CLEAR-IT 2 Investigators. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596559null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Joe-Hollyfield-PhD-receives-2009-Proctor-Meda/ArticleStandard/Article/detail/596563?contextCategoryId=43981&ref=25 Joe Hollyfield, PhD, received the distinguished Proctor Medal, the highest honor bestowed by the Association for Research in Vision and Ophthalmology. Dr. Hollyfield, director of ophthalmic research, Cole Eye Institute, Cleveland Clinic, Cleveland, delivered the Proctor Lecture titled "Progress in Understanding the Initiating Events in Age-Related Macular Degeneration [AMD]." While at the Cleveland Clinic, his laboratory identified the composition of drusen, the major risk factor for AMD. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596563null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Endothelial-keratoplasty-Graft-survival-and-e/ArticleStandard/Article/detail/596546?contextCategoryId=43981&ref=25 Long-term data on deep lamellar endothelial keratoplasty (DLEK) show that most donor tissue remains clear past the 5-year follow-up. Data from a newer procedure, Descemet's stripping automated endothelial keratoplasty (DSAEK), also are promising and indicate an earlier plateau of endothelial cell loss, said Mark A. Terry, MD, director of corneal services, Devers Eye Institute, Portland, OR. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596546null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Integrin-antagonist-well-tolerated-safe-for-e/ArticleStandard/Article/detail/596560?contextCategoryId=43981&ref=25 A small-molecule integrin antagonist (JSM 6427, Jerini Ophthalmic) administered intravitreally to 28 patients in a phase I multicenter open-label study showed a trend toward increased best-corrected visual acuity (BCVA) in patients treated with one dose of the drug. The results were less dramatic in patients who required repeated dosing, said Anthony Capone, MD, clinical associate professor of ophthalmology, Oakland University, Royal Oak, MI. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596560null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Risk-factors-for-post-cataract-surgery-endoph/ArticleStandard/Article/detail/596545?contextCategoryId=43981&ref=25 A study examining potentially modifiable risk factors to reduce post-cataract surgery endophthalmitis found that antibiotic injections during surgery could reduce the risk, however, it was questionable whether the preoperative or postoperative use of antibiotic drops or ointments was beneficial, said Emily W. Gower, PhD, assistant professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore. She also is director of the Wilmer Clinical Research Unit and holds a joint appointment in epidemiology in the Bloomberg School of Public Health. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596545null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Aptamer-and-ranibizumab-safe-may-be-efficacio/ArticleStandard/Article/detail/596561?contextCategoryId=43981&ref=25 A phase I study of an intravitreal anti-platelet-derived growth factor (PDGF) aptamer (E10030, Ophthotech) that targets pericytes, evaluated in combination therapy with ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (AMD), indicated that the drug is safe and seems to have biologic activity against choroidal neovascularization (CNV), said David Boyer, MD, of Retina-Vitreous Associates, Beverly Hills. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596561null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Weisenfeld-Lecture-Progress-being-made-toward/ArticleStandard/Article/detail/596564?contextCategoryId=43981&ref=25 World-renowned retinal specialist Alan Bird, MD, FMedSci, University College London Institute of Ophthalmology and Moorfields Eye Hospital, London, received the Mildred Weisenfeld Award Monday evening and presented a lecture on progress toward biological treatment of retinal diseases. In his long career, Dr. Bird has made many contributions to the study of genetic and degenerative retinal disorders. 2009-05-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596564null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Epidemiologic-trends-observed-in-study-of-dis/ArticleStandard/Article/detail/596383?contextCategoryId=43981&ref=25 Several major epidemiologic trends are apparent in the study of disparities in eye diseases. One decades-long trend has been a steady shift from infectious to chronic sources of disease and mortality. The leading causes of blindness and visual impairment worldwide are cataract and glaucoma, whereas trachoma, once the second-leading cause, now is further down the list, said Debra A. Schaumberg, ScD, OD, MPH, associate professor, Department of Epidemiology, Harvard School of Public Health, Boston. 2009-05-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596383null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Researchers-assess-effect-of-vision-impairmen/ArticleStandard/Article/detail/596411?contextCategoryId=43981&ref=25 Recent research on hemianopia shows that many individuals with this form of visual field loss can safely drive, a finding that has policy and scientific implications. Researchers at the University of Alabama, Birmingham, recruited 30 older drivers with hemianopia or quadrantanopia and an equal number with normal visual fields for an on-road driving performance study. During the test, each driver was accompanied by two masked evaluators, sitting in the back seat, and a certified driving rehabilitation specialist in the front seat, who had her own set of controls for the vehicle. The on-road test was recorded on a four-channel video system. 2009-05-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596411null HTML